Oxford Immunotec (OXFD) Tops Q1 EPS by 10c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Oxford Immunotec Reports First Quarter 2019 Financial Results
May 9, 2019 7:00 AM EDTFirst quarter revenue of $14.8 million, an increase of 27% compared to prior year periodGross margins expanded 360bps to 71.4%86% reduction in net loss to $1.5m
OXFORD, United Kingdom and MARLBOROUGH, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the Company), a global, high-growth diagnostics company, today announced first quarter 2019 financial results.
The Company got off to a strong start in 2019 with robust growth in all geographies and continued execution on our strategic priorities said Dr. Peter Wrighton-Smith, Chief Executive Officer... More
